Vascular normalization, achieved with low-dose anti-angiogenic agents, enhances immunotherapy efficacy and reduces toxicity and the FDA has approved combinations of PD1/PD-LI antibodies with anti-VEGF/VEGFR agents in lung and renal cancers. The gene discussed is PDCD1; the disease is renal carcinoma.